The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
March 7th 2024
The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies
1.5 Credits / Hematology, Oncology
View More
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
Analysis Finds Clinical Insights for Treating AIHA, Non-Hodgkin Lymphoma
February 22nd 2020Though rare, patients with both autoimmune hemolytic anemia (AHIA) and non-Hodgkin lymphoma face stark odds of long-term survival. A new study lends insights into how to best diagnose and treat those patients.
Read More
Rogue Cell Communications Lead to Leukemia, Study Finds
February 15th 2020Through a series of live-cell single-molecule imaging experiments, researchers at the University of York discovered how rogue communications between cells lead to leukemia, according to a recent study published in Science.
Read More
Cost-effectiveness of Brentuximab Vedotin With Chemotherapy in Treatment of CD30-Expressing PTCL
An economic model based on the ECHELON-2 trial demonstrated cost-effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma (PTCL).
Read More
Wave of Targeted CLL Therapies Raises Questions About Autoimmune Complications
February 5th 2020New targeted therapies like ibrutinib, idelalisib, and venetoclax appear to be highly successful in the treatment of chronic lymphocytic leukemia (CLL), but investigators say it’s unclear how those therapies impact autoimmune complications of the cancer.
Read More
Dr Adam Olszewski on Growing Ibrutinib Use to Treat CLL
February 4th 2020Ibrutinib quickly became the de fact standard of care to treat chronic lymphocytic leukemia, but the high price presents a problem for the US healthcare system, said Adam Olszewski, MD, associate professor of medicine at The Warren Alpert Medical School of Brown University.
Watch
Dr Sarah Tasian Discusses Challenges to Overcome When New Therapies Come to Market for Pediatric AML
January 28th 2020As new therapies come to market for pediatric acute myeloid leukemia, there will be a lot of questions to answer regarding dosing and where these drugs are used in the patient journey, said Sarah Tasian, MD, attending physician in the Division of Oncology at Children’s Hospital of Philadelphia.
Watch
The abstract presented by Kwanza Price, MPH, of Jazz Pharmaceuticals, gathered data from August 1, 2017, and February 28, 2019, capturing the first 19 months of claims data after the biotech received FDA approval for its fixed-dose therapy for 2 types of poor-prognosis acute myeloid leukemia.
Read More
Dr Adam Olszewski Discusses Challenges With Using Ibrutinib as a First-Line Therapy in CLL
January 20th 2020While ibrutinib is a major breakthrough in treating chronic lymphocytic leukemia, it is associated with financial burdens and medical concerns for the older patients being treated, said Adam Olszewski, MD, associate professor of medicine at The Warren Alpert Medical School of Brown University.
Watch
Dr Lena Winestone Outlines Barriers to Care and Disparities Among Children With Leukemia
January 12th 2020Financial barriers and perceived implicit biases were both barriers that families of children with acute leukemia raised regarding access to care issues that might have delayed diagnosis, said Lena Winestone, MD, assistant professor of pediatrics at the University of California, San Francisco.
Watch
Dr Sarah Tasian Highlights Exciting New Advances Coming to Pediatric AML
January 9th 2020Sarah Tasian, MD, attending physician in the Division of Oncology at Children’s Hospital of Philadelphia, highlights the coming advances in pediatric acute myeloid leukemia (AML) that she is the most excited for.
Watch
Dr Lena Winestone Highlights Impact Neighborhood Has on Outcomes in Pediatric Cancer
January 4th 2020Since there are aspects of care in clinical trials that might not be mandated, research is being done to see whether there are socioeconomic disparities for things like supportive care for children with cancer, said Lena Winestone, MD, assistant professor of pediatrics at the University of California, San Francisco.
Watch
Dr Lena Winestone on Understanding the Cause of Disparities in Pediatric AML in Order to Intervene
December 24th 2019Lena Winestone, MD, assistant professor of pediatrics at the University of California, San Francisco, explains how her research into disparities in pediatric acute myeloid leukemia (AML) may help identify the cause of those disparities and how best to intervene in order to improve outcomes for these patients.
Watch
Dr Lindsey Roeker: Novel Agents Have Revolutionized CLL Treatment
December 21st 2019The introduction of novel agents has really revolutionized the care of patients with chronic lymphocytic leukemia to the point where chemotherapy is rarely used, said Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center.
Watch
Dr Sarah Tasian Highlights Challenges With Improving Outcomes in Pediatric AML
December 18th 2019One of the challenges with treating children with acute myeloid leukemia is that many of the novel drugs are not available in children. Current treatment with chemotherapy really requires balancing increasing doses with the short-term and long-term toxicities, said Sarah Tasian, MD, attending physician in the Division of Oncology at Children’s Hospital of Philadelphia.
Watch